New combo therapy offers hope for hard-to-treat blood cancer
NCT ID NCT07093710
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining the drug golidocitinib with either mitoxantrone liposome or chidamide can safely shrink tumors in people with peripheral T-cell lymphoma that has returned or not responded to prior therapy. About 101 adults will receive one of the combinations. The goal is to see how many patients achieve remission and to find the best dose with the fewest side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University
RECRUITINGGuangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple blood test spot lymphoma earlier?
- Can a Five-Drug combo tame a tough lymphoma without standard chemo?
- Can a targeted pill boost Chemotherapy's punch against a rare lymphoma?
- A microchip implanted in tumors could reveal which drugs work best
- Can a cancer drug reboot the immune system after a stem cell transplant?
- Experimental drug combo aims to tackle tough lymphoma